latest news releases from the newsroom
Michael Brown, M.D., Ph.D. and Judy Brown, Research Consultants, Rejoin Bioheart's Clinical Team to Increase Support of Clinical Trials
SUNRISE, Fla., March 12, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Pink Sheets:BHRT) announced today that Dr. Michael Brown and Mrs. Judy Brown, research consultants, have rejoined Bioheart's clinical team to provide increased support to its clinical trials. Dr. Brown previously served as Bioheart's Chief Scientific Officer and Vice President of Clinical Affairs from 1999 to 2004 and as a consulting Senior Clinical Specialist from January 2005 to December 2006. Prior to that, he was a clinical specialist at Medtronic, Inc. Judy Brown was previously Director of Clinical Research at World Medical Manufacturing Corporation from May 1998 to August 2000 and served as a consultant for World Medical in 2001. Prior to this work, she coordinated clinical trials at the Baptist Cardiac & Vascular Institute, Miami, from 1990 to 1997. Her prior experience was in basic science research at the University of Miami, where the two met. They have 40 years of combined basic science and clinical research management experience between them.
FCStone Group, Inc.
FCStone Group, Inc. Completes Transfer of Energy Trading Account
KANSAS CITY, Mo., March 12, 2009 (GLOBE NEWSWIRE) -- FCStone Group, Inc. (Nasdaq:FCSX), an integrated commodity risk management firm, reported today that it has transferred to a third party substantially all of the positions and liability related to a previously-reported energy trading customer account which had experienced significant losses. The transfer of the positions eliminates all material future exposure of FCStone to the account, for which FCStone provided clearing and execution services on a third-party basis, and preserves FCStone's total available capital well in excess of regulatory requirements as FCStone moves forward.
MediciNova Sends Letter to Avigen Board of Directors
SAN DIEGO, March 12, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today sent the following letter to the Board of Directors of Avigen, Inc.:
The Board of Directors of MSC.Software Names Ashfaq Munshi Interim CEO and President
SANTA ANA, Calif., March 12, 2009 (GLOBE NEWSWIRE) -- MSC.Software Corporation (Nasdaq:MSCS) today announced that the Board of Directors has named Ashfaq A. Munshi interim Chief Executive Officer and President of the Company. These actions followed the decision of William J. Weyand, Chairman and CEO and Glenn Weinkoop, President and COO to resign from MSC after four years. The Board of Directors also named current board members Donald Glickman and Robert A. Schriesheim to serve as non-executive co-chairmen, effective immediately.